Monoclonal Antibody Therapeutics Market Scope And Analysis

Report Code : TIPRE00003417
Category : Pharmaceuticals

No. of Pages : 150

Buy Now

Monoclonal Antibody Therapeutics (mABs) Market Analysis, Size, and Growth (2021-2022)

Buy Now

Monoclonal Antibody Therapeutics (mABs) Market Report Scope

Report Attribute	Details
Market size in 2022	US$ 192.04 Billion
Market Size by 2030	US$ 542.80 Billion
Global CAGR (2022 - 2030)	13.9%
Historical Data	2020-2022
Forecast period	2022-2030
Segments Covered	By Product Recombinant mABs Antibody Drug Conjugates Bispecific and Multispecific mABs Biosimilars By Application Oncology Autoimmune Disease By Distribution Channel Hospital Pharmacies Retail Pharmacies
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	GlaxoSmithKline F Hoffmann La Roche Bayer AG Amgen Novartis AbbVie Bristol Myers Squibb Janssen Pharmaceutical Merck KgaA

Monoclonal antibody therapeutics (mABs) Industry Developments and Future Opportunities:

Various strategic developments by leading players operating in the monoclonal antibody therapeutics (mABs) market are listed below:

In January 2023, AstraZeneca received approval for Evusheld in the European Union (EU). Evusheld is a combination of two long-acting antibodies—tixagevimab (AZD8895) and cilgavimab (AZD1061). The US government extended support for the development of this product through federal funds from the Department of Health and Human Services, the Administration for Strategic Preparedness and Response, and the Biomedical Advanced Research and Development Authority.
In August 2023, Regeneron Pharmaceuticals, Inc. entered into an agreement with the Biomedical Advanced Research and Development Authority (BARDA) to support clinical development, clinical manufacturing, and the regulatory licensure process for next-generation monoclonal antibody therapy against COVID-19. Under this agreement, Regeneron plans to work collaboratively with BARDA to evaluate and further develop and manufacture this therapy, and conduct regulatory activities.

Competitive Landscape and Key Companies:

GlaxoSmithKline, F.Hoffmann-La-Roche, Bayer AG, Amgen, Novartis, AbbVie, Bristol-Myers Squibb, Janssen Pharmaceutical, Merck KgaA, and AstraZeneca are among the prominent companies in the monoclonal antibody therapeutics (mABs) market. The monoclonal antibody therapeutics (mABs) market report includes company positioning and concentration to evaluate the performance of key players in the market.